氟尿嘧啶/水杨酸(Fluorouracil/Salicylic acid) - 药物靶点：COX x TYMS_在研适应症：光化性角化病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Actikerall

靶点

COX x TYMS

作用机制

COX抑制剂(环氧化酶抑制剂)、TYMS抑制剂(胸苷酸合成酶抑制剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

光化性角化病

非在研适应症-

原研机构

Almirall SA

在研机构

A. Menarini Industrie Farmaceutiche Riunite SRL

Almirall SA

非在研机构-

最高研发阶段批准上市

首次获批日期

瑞士 (2011-04-13),

光化性角化病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C11H9FN2O5

InChIKeyIGUGGVZJRPHVBU-UHFFFAOYSA-N

CAS号1399855-43-6

关联

4

项与氟尿嘧啶/水杨酸相关的临床试验

NCT02289768 / Completed临床3期

Multicentre, Randomized, Parallel, Double-Blind, Vehicle Controlled Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In The Field-Directed Treatment Of Actinic Keratoses Grade I To II (Field Cancerization)

The main purpose of this vehicle-controlled study is to determine the efficacy and safety of a solution of Actikerall® (containing 5-fluorouracil 0.5% and salicylic acid 10.0%) in the field-directed treatment of grade I-II actinic keratosis, when it is applied to the affected area once daily for 12 weeks.
A secondary objective of this study is to evaluate the efficacy of Actikerall® solution on subclinical actinic keratosis lesions in a subset of patients.

开始日期2014-10-01

申办/合作机构

Almirall SA

[+1]

NCT01358851 / Completed临床2期

A Prospective Comparator Controlled Randomized Exploratory Study on the Efficacy of LAS 41005 Compared to Cryotherapy in Subjects With Hyperkeratotic Actinic Keratosis

The aim of this study is to evaluate the efficacy and safety of LAS 41005 compared to cryotherapy in subjects with moderate to severe hyperkeratotic actinic keratosis (punch biopsies).

开始日期2011-04-01

申办/合作机构

Almirall SA

EUCTR2010-022980-37-DE / Not yet recruitingN/A

A prospective comparator controlled randomized exploratory study on the efficacy of LAS 41005 compared to cryotherapy in subjects with hyperkeratotic actinic keratosis

开始日期2010-12-09

申办/合作机构

Almirall Hermal GmbH

100 项与氟尿嘧啶/水杨酸相关的临床结果

登录后查看更多信息

100 项与氟尿嘧啶/水杨酸相关的转化医学

登录后查看更多信息

100 项与氟尿嘧啶/水杨酸相关的专利（医药）

登录后查看更多信息

5

项与氟尿嘧啶/水杨酸相关的文献（医药）

2022-07-04·Journal of Dermatological Treatment

Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study

Article

作者: Geraci, Francesco ; Lozzi, Flavia ; Cosio, Terenzio ; Gaeta Shumak, Ruslana ; Bianchi, Luca ; Garofalo, Virginia ; Di Raimondo, Cosimo ; Lanna, Caterina ; Campione, Elena ; Lambiase, Sara ; Diluvio, Laura ; Di Prete, Monia

BACKGROUNDActinic keratosis is one of the most common dermatological disorders. A new topical solution, constituted by 0.5% 5-fluorouracil and 10% salicylic acid (Actikerall, Almirall) has been introduced in the treatment pipeline of hyperkeratotic actinic keratoses of the head and neck.PATIENTS AND METHODSWe analyzed in an observational prospective clinical study the short-term treatment effectiveness of 5-fluorouracil and salicylic acid on face and scalp actinic keratoses of grade 1 and 2 of 40 patients. Efficacy assessment was performed by clinical dermatological examination, collecting color photographs, calculating AKASI score, and by means of dermoscopy for each target lesion at every visit.RESULTSAKASI score decreased from an initial score of 3.3 to a final score of 0.9. At week 4, we were able to record a complete clearance of 50% of the treated lesions and a partial clearance of 28%. At the end of 12 weeks, 84% of the total lesions showed complete clearance, while 8% had partial clearance.CONCLUSIONS5-fluorouracil and salicylic acid topical solution is effective in the treatment of mild to moderate actinic keratoses. In the future, further studies are needed to evaluate the chance of adjusting drug dosage according to patients' and actinic keratoses features.

2018-03-01·Clinical and Experimental Dermatology

Actikerall: an alternative to curettage for some seborrhoeic keratoses?

Letter

作者: Hampton, P. ; Goodhead, C.

2016-11-01·Journal of Cutaneous Medicine and Surgery4区 · 医学

Low-Dose 0.5% 5-Fluorouracil/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses

4区 · 医学

Review

作者: Morton, Colin ; Roldán-Marín, Rodrigo ; Azeredo, Rosario Rodríguez ; Herranz, Pedro ; Dirschka, Thomas

Background: Actinic keratosis (AK) lesions have the potential to develop into invasive squamous cell carcinomas (SCCs), and approaches to treatment are evolving to try to reduce the burden of SCC. Objective: To present the published clinical research surrounding the use of 0.5% 5-fluorouracil with 10% salicylic acid (low-dose 5-FU/SA) for the treatment of hyperkeratotic AKs. Method: A review of published clinical evidence for low-dose 5-FU/SA for the treatment of AKs. The articles were selected following a MEDLINE database search of the combined terms fluorouracil, salicylic acid and actinic keratosis which represent the peer review publications of clinical studies that primarily investigate the use of Actikerall in AK. Results: Combining low-dose 5-FU with keratolytic SA is associated with high rates of histologic clearance, reduction in lesion number/area, and sustained clinical response in clinical study and the clinical practice setting. Low-dose 5-FU/SA has also been evaluated using imaging to detect the progression of subclinical AK lesions through a course of the field-directed treatment. Conclusion: Low-dose 5-FU/SA is an effective and well-tolerated treatment option licensed for the lesion-directed treatment of mild-to-moderate hyperkeratotic AK lesions.

1

项与氟尿嘧啶/水杨酸相关的新闻（医药）

2024-01-11

·PRNewswire

Almirall Digital Transformation Strategy Analysis Report 2023: Accelerators, Incubators, and Other Innovation Programs

DUBLIN, Jan. 10, 2024 /PRNewswire/ -- The "Almirall - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering. This report provides insights into Almirall's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. Almirall is a global biopharmaceutical company specializing in dermatology. The company develops and commercializes solutions for the treatment of a variety of dermatological diseases such as acne, atopic dermatitis, actinic keratosis, and psoriasis among others. Some of the company's key products are Ilumetri (for moderate-to-severe plaque psoriasis), Wynora cream (for mild-to-moderate plaque psoriasis), Skilarence (for moderate-to-severe plaque psoriasis), Seysara (for acne), Ciclopoli (for onychomycosis), and Klisyri, Actikerall, and Solaraze (for actinic keratosis). The company also produces medicines for the neurological, gastric, and cardiac diseases. The company's key dermatological products have been used by 324,000 people since their launches. Scope Almirall is leveraging several emerging technologies to quickly discover drugs, drive sales, streamline production, expand market presence and help patients recover quickly. Cloud, AI, and digital therapeutics are among the technologies the company is focusing on. Almirall launched its dermatology digital health accelerator, Digital Garden, in 2020 to support startups that are focused on developing technology-based services and solutions for various dermatological diseases. In 2023, Almirall partnered with NTT Data to accelerate the process of extracting information from medical papers. Reasons to Buy Gain insights into Almirall's technology initiatives. Gain insights into its digital strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into its various technology launches and partnerships. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and Other Innovation Programs Technology Focus Technology Initiatives Partnership Network Map ICT Budget and Contracts Key Executives A selection of companies mentioned in this report includes NTT Data ZeClinics Iktos Clariba For more information about this company profile visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

100 项与氟尿嘧啶/水杨酸相关的药物交易

登录后查看更多信息